OncoMatch/Clinical Trials/NCT06298916
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Is NCT06298916 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies 64Cu-LNTH-1363S for metastatic sarcoma.
Treatment: 64Cu-LNTH-1363S — This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Esophageal Carcinoma
Gastric Cancer
Pancreatic Cancer
Colorectal Cancer
Biomarker criteria
Required: FAP overexpression (suspected FAP-expressing)
suspected FAP-expressing metastatic sarcoma (Part 1); suspected FAP expressing sarcoma or GIT cancers (Part 2)
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: systemic anti-cancer therapy
Cannot have received: neoadjuvant anti-cancer therapy
Lab requirements
Kidney function
calculated creatinine clearance ≥ 60 ml/min (cockcroft gault equation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UC Irvine Health - Chao Family Comprehensive Cancer Center · Orange, California
- Stanford Hospital & Clinics · Stanford, California
- BAMF Health, Inc. · Grand Rapids, Michigan
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify